Understand the source comparison
Cognitive Enhancement Peptides 2026: Comparison Table
Cerebrolysin NGF/BDNF mimetic, GABAergic modulation 200+ trials in stroke, TBI, dementia; no healthy-adult cognitive enhancement trials 10–30ml IM daily, 10–20 day cycles Most clinical evidence, but all in disease models. No data for baseline cognitive enhance
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cerebrolysin
- NGF/BDNF mimetic, GABAergic modulation
- 200+ trials in stroke, TBI, dementia; no healthy-adult cognitive enhancement trials
- 10–30ml IM daily, 10–20 day cycles
- Most clinical evidence, but all in disease models. No data for baseline cognitive enhancement
- Dihexa
- HGF receptor activation, synaptogenesis
- Zero published human trials as of 2026
- 1–10mg subcutaneous, protocols vary
- Extraordinary preclinical potency, complete absence of human safety or efficacy data
- P21
- CREB-mediated LTP enhancement
- Zero published human trials
- 1–5mg subcutaneous weekly
- Strong hippocampal plasticity signals in rodents, purely anecdotal in humans
- Semax
- BDNF upregulation, dopamine modulation
- Small Russian trials in stroke recovery; no placebo-controlled cognitive enhancement studies
- 300–600mcg intranasal daily
- Used clinically in Russia for decades, minimal Western validation